Human dendritic cells and transplant outcome

Transplantation

Volumn 85, Issue 11, 2008, Pages 1513-1522

  Solari, Mario G ^a,b   Thomson, Angus W ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow transplantation; Dendritic cells; Human; Organ transplantation

Indexed keywords

ALEMTUZUMAB; ANTIINFLAMMATORY AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYTOMEGALOVIRUS VACCINE; EPSTEIN BARR VIRUS VACCINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ALLOIMMUNITY; ALLOTRANSPLANTATION; ANTIGEN PRESENTING CELL; BIODIVERSITY; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL COUNT; CELL FATE; CELL FUNCTION; CELL GROWTH; CELL ISOLATION; CELL MIGRATION; CELL TRANSPLANTATION; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION PREVENTION; LEUKEMIA; LEYDIG CELL; MONOTHERAPY; NERVE CELL PLASTICITY; NONHUMAN; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; RECIPIENT; REVIEW; TRANSPLANTATION TOLERANCE; TREATMENT RESPONSE; VIRUS INFECTION; ANIMAL; AUTOIMMUNITY; GRAFT SURVIVAL; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; DENDRITIC CELLS; GRAFT SURVIVAL; HOST VS GRAFT REACTION; HUMANS;

EID: 47049125098     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318173a768     Document Type: Review

References (111)

1. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137: 1142.
2. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med 1974; 139: 380.
3. Bashyam H. Ralph Steinman: Dendritic cells bring home the Lasker. J Exp Med 2007; 204: 2245.
4. Steinman RM. The dendritic cell system and its role in immunogenic-ity. Annu Rev Immunol 1991; 9: 271.
5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245.
6. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685.
7. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007; 7: 19.
8. Wu L, Liu YJ. Development of dendritic-cell lineages. Immunity 2007; 26: 741.
9. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7: 610.
10. Lotze MT, Thomson AW, eds. Dendritic cells: Biology and clinical applications, [ed. 2]. London, San Diego, Academic Press 2001, pp 1.
11. Mazariegos GV, Zahorchak AF, Reyes J, et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 2003; 3: 689.
12. Bosma BM, Metselaar HJ, Mancham S, et al. Characterization of human liver dendritic cells in liver grafts and perfusates. Liver Transpl 2006; 12: 384.
13. vanHaarst JM, deWit HJ, Drexhage HA, et al. Distribution and immu-nophenotype of mononuclear phagocytes and dendritic cells in the human lung. Am J RespirCell Mol Biol 1994; 10: 487.
14. Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: From specific surface markers to specific cellular functions. Hum Im-munol 2002; 63: 1133.
15. Hackstein H, Renner FC, Bohnert A, et al. Dendritic cell deficiency in the blood of kidney transplant patients on long-term immunosuppression: Results of a prospective matched-cohort study. Am J Transplant 2005; 5: 2945.
16. Tokita D, Mazariegos GV, Zahorchak AF, et al. High PD-L1/CD86 ratio on plasmacytoid DC correlates with elevated T regulatory cell frequency in operational liver transplant tolerance. Transplantation 2008; 85: 369.
17. Hart DN, Fuggle SV, Williams KA, et al. Localization of HLA-ABC and DR antigens in human kidney. Transplantation 1981; 31: 428.
18. Prickett TC, McKenzie JL, Hart DN. Characterization of interstitial dendritic cells in human liver. Transplantation 1988; 46: 754.
19. Ballardini G, Fallani M, Bianchi FB, et al. Antigen presenting cells in liver biopsies from patients with primary biliary cirrhosis. Autoimmunity 1989; 3: 135.
20. Leprini A, Valente U, Celada F, et al. Morphology, cytochemical features, and membrane phenotype of HLA-DR+ interstitial cells in the human pancreas. Pancreas 1987; 2: 127.
21. Lu W, PipeleersDG, Kloppel G, etal. Comparative immunocytochem-ical study of MHC class II expression in human donor pancreas and isolated islets. Virchows Arch 1996; 429: 205.
22. Woltman AM, deFijter JW, Zuidwijk K, et al. Quantification of dendritic cell subsets in human renal tissue under normal and pathological conditions. Kidney Int 2007; 71: 1001.
23. Daniel V, Naujokat C, Sadeghi M, et al. Association of circulating interleukin (IL)-12- and IL-10-producing dendritic cells with time posttransplant, dose of immunosuppression, and plasma cytokines in renal-transplant recipients. Transplantation 2005; 79: 1498.
24. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med 1990; 171: 307.
25. Larsen CP, Steinman RM, Witmer-Pack M, et al. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 1990; 172: 1483.
26. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982; 155: 31.
27. Brewer Y, Palmer A, Taube D, et al. Effect of graft perfusion with two CD45 monoclonal antibodies on incidence of kidney allograft rejection. Lancet 1989; 2: 935.
28. Goldberg LC, Bradley JA, Connolly J, et al. Anti-CD45 monoclonal antibody perfusion of human renal allografts prior to transplantation. A safety and immunohistological study. CD45 Study Group. Transplantation 1995; 59: 1285.
29. Starzl TE, Demetris AJ, Murase N, et al. Cell migration, chimerism, and graft acceptance [see comments]. Lancet 1992; 339: 1579.
30. Starzl TE, Demetris AJ, Trucco M, et al. Cell migration and chimerism after whole-organ transplantation: The basis of graft acceptance. Hepa-tology 1993; 17: 1127.
31. Thomson AW, Lu L, Murase N, et al. Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells 1995; 13: 622.
32. Burlingham WJ, Grailer AP, Fechner JH Jr, et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 1995; 59: 1147.
33. Lu L, Rudert WA, Qian S, et al. Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony stimulating factor. J Exp Med 1995; 182: 379.
34. Rugeles MT, Aitouche A, Zeevi A, et al. Evidence for the presence of multilineage chimerism and progenitors of donor dendritic cells in the peripheral blood of bone marrow-augmented organ transplant recipients. Transplantation 1997; 64: 735.
35. Morelli AE, Thomson AW. Dendritic cells: Regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev 2003; 196: 125.
36. O'Connell PJ, Burlingham WJ. Donor dendritic cell persistence in organ allograft recipients in the absence of immunosuppression. J Leukoc Biol 1999; 66: 301.
37. Cai J, Lee J, Jankowska-Gan E, et al. Minor H antigen HA-1-specific regulator and effector CD8+ T cells, and HA-1 microchimerism, in allograft tolerance. J Exp Med 2004; 199: 1017.
38. Derks RA, Jankowska-Gan E, Xu Q, et al. Dendritic cell type determines the mechanism of bystander suppression by adaptive T regulatory cells specific for the minor antigen HA-1. J Immunol 2007; 179: 3443.
39. Hesselink DA, Betjes MG, Verkade MA, et al. The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. Nephrol Dial Transplant 2005; 20: 1868.
40. Lim WH, Kireta S, Thomson AW, et al. Renal transplantation reverses functional deficiencies in circulating dendritic cell subsets in chronic renal failure patients. Transplantation 2006; 81: 160.
41. McKerrow KJ, Hawthorn RJ, Thompson W. An investigation of circulating and in situ lymphocyte subsets and Langerhans cells in the skin and cervix of patients with chronic renal failure. Br J Dermatol 1989; 120: 745.
42. Womer KL, Peng R, Patton PR, et al. The effects of renal transplantation on peripheral blood dendritic cells. Clin Transpl 2005; 19: 659.
43. Bosma BM, Metselaar HJ, Tra WM, et al. Impairment of circulating myeloid dendritic cells in immunosuppressed liver transplant recipients. Clin Exp Immunol 2007; 149: 525.
44. Hackstein H, Thomson AW. Dendritic cells: Emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4: 24.
45. Shodell M, Shah K, Siegal FP. Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration. Lupus 2003; 12: 222.
46. Boor PP, Metselaar HJ, Mancham S, et al. Prednisolone suppresses the function and promotes apoptosis of plasmacytoid dendritic cells. Am J Transplant 2006; 6: 2332.
47. Mazariegos GV, Zahorchak AF, Reyes J, et al. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant 2005; 5: 314.
48. Sebelin K, Schulzki A, Kloetzel PM, et al. Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients. Transplantation 2006; 82: 779.
49. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with ale-mtuzumab. Blood 2002; 100: 1715.
50. Kirsch BM, Haidinger M, Zeyda M, et al. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients. Transpl Immunol 2006; 16: 254.
51. Barten MJ, Garbade J, Bittner HB, et al. Affects of immunosuppression on circulating dendritic cells: An adjunct to therapeutic drug monitoring after heart transplantation. Int Immunopharmacol 2006; 6: 2011.
52. Suda T, Chida K, Matsuda H, et al. High-dose intravenous glucocorti-coid therapy abrogates circulating dendritic cells. J Allergy Clin Immunol 2003; 112: 1237.
53. Fang L, Fehse B, Engel M,et al. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation 2005; 79: 369.
54. Vuckovic S, Kim M, Khalil D, et al. Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression. Blood 2003; 101: 2314.
55. Shi H, Ge J, Fang W, et al. Peripheral-blood dendritic cells in men with coronary heart disease. Am J Cardiol 2007; 100: 593.
56. Athanassopoulos P, Vaessen LM, Maat AP, et al. Peripheral blood dendritic cells in human end-stage heart failure and the early post-transplant period: Evidence for systemic Th1 immune responses. Eur J Cardiothorac Surg 2004; 25: 619.
57. Teig N, Moses D, Gieseler S, et al. Age-related changes in human blood dendritic cell subpopulations. Scand J Immunol 2002; 55: 453.
58. Ho CS, Lopez JA, Vuckovic S, et al. Surgical and physical stress increases circulating blood dendritic cell counts independently of mono-cyte counts. Blood 2001; 98: 140.
59. Gerrits JH, Athanassopoulos P, Vaessen LM, et al. Peripheral blood manipulation significantly affects the result of dendritic cell monitoring. Transpl Immunol 2007; 17: 169.
60. Field K, Vuckovic S, Hart DN. Dendritic cells. In: Lotze MT, Thomson AW, eds. Measuring immunity: Basic biology and clinical assessment. Amsterdam, Elsevier Academic Press 2005, pp 290.
61. Vuckovic S, Gardiner D, Field K, et al. Monitoring dendritic cells in clinical practice using a new whole blood single-platform TruCOUNT assay. J Immunol Methods 2004; 284: 73.
62. Lau J, Sartor M, Bradstock KF, et al. Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease. Transplantation 2007; 83: 839.
63. Talarn C, Urbano-Ispizua A, Martino R, et al. Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome. Haematologica 2007; 92: 1655.
64. Mohty M, Blaise D, Faucher C, et al. Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia 2005; 19: 1.
65. Reddy V, Iturraspe JA, Tzolas AC, et al. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood 2004; 103: 4330.
66. Chan GW, GorgunG,Miller KB,etal. Persistenceof host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 170.
67. Athanassopoulos P, Vaessen LM, Balk AH, et al. Impaired circulating dendritic cell reconstitution identifies rejecting recipients after clinical heart transplantation independent of rejection therapy. Eur J Cardio-thorac Surg 2005; 27: 783.
68. Sorrentino C, Scarinci A, D'Antuono T, et al. Endomyocardial infiltration by B and NK cells foreshadows the recurrence of cardiac allograft rejection. J Pathol 2006; 209: 400.
69. Takebayashi M, Amakawa R, Tajima K, et al. Blood dendritic cells are decreased in acute graft-versus-host disease. Bone Marrow Transplant 2004; 33: 989.
70. Vakkila J, Thomson AW, Hovi L, et al. Circulating dendritic cell subset levels after allogeneic stem cell transplantation in children correlate with time post transplant and severity of acute graft-versus-host disease. Bone Marrow Transplant 2005; 35: 501.
71. Auffermann-GretzingerS,Eger L, Bornhauser M, etal. Fast appearance of donor dendritic cells in human skin: Dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantation. Transplantation 2006; 81: 866.
72. Collin MP, Munster D, Clark G, et al. In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: Implications for the control of Graft-versus-host disease. Transplantation 2005; 79: 722.
73. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: A meta-analysis. J Clin Oncol 2001; 19: 3685.
74. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: Does the source of hematopoietic stem cells matter? Blood 2001; 98: 2900.
75. Waller EK, Rosenthal H, Jones TW, et al. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 2001; 97: 2948.
76. Arpinati M, Green CL, Heimfeld S, et al. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95:2484.
77. Arpinati M, Chirumbolo G, Urbini B, et al. Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2003; 11: 345.
78. Clark FJ, Freeman L, Dzionek A, et al. Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease. Transplantation 2003; 75: 221.
79. Vela-Ojeda J, Garcia-Ruiz EMA, Reyes-Maldonado E, et al. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation. Ann Hematol 2006; 85: 113.
80. Athanassopoulos P, Vaessen LM, Maat AP, et al. Preferential depletion of blood myeloid dendritic cells during acute cardiac allograft rejection under controlled immunosuppression. Am J Transplant 2005; 5(4 Pt 1): 810.
81. Saresella M, Marini M, Guerini F, et al. Peripheral blood dendritic cells increase in kidney-transplant patients without rejection. Clin Immunol 2004; 110: 191.
82. Sato K, Yamashita N, Yamashita N, et al. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003; 18:367.
83. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233.
84. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8( + ) regulatory T cells in vivo in humans. Blood 2002; 100: 174.
85. Nencioni A, Grunebach F, Schmidt SM, et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 2008; 65: 191.
86. Vulink A, Radford KJ, Melief C, et al. Dendritic cells in cancer immunotherapy. Adv Cancer Res 2008; 99: 363.
87. Palucka AK, Ueno H, Fay JW, et al. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220: 129.
88. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419.
89. Fearnley DB, Whyte LF, Carnoutsos SA, et al. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood 1999; 93: 728.
90. Wong EC, Lee SM, Hines K, et al. Development of a closed-system process for clinical-scale generation of DCs: Evaluation of two monocyte-enrichment methods and two culture containers. Cytotherapy 2002; 4:65.
91. Zahorchak AF, Kean LS, Tokita D, et al. Infusion of stably immature monocyte-derived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques. Transplantation 2007; 84: 196.
92. Moseman EA, Liang X, Dawson AJ, et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004; 173: 4433.
93. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoprolif-erative disorders. Annu Rev Med 2005; 56: 29.
94. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
95. Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273.
96. Fitzgerald JT, Gallay B, Taranto SE, et al. Pretransplant recipient cytomegalovirus seropositivity and hemodialysis are associated with decreased renal allograft and patient survival. Transplantation 2004; 77: 1405.
97. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549.
98. Subklewe M, Sebelin K, Block A, et al. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells. Hum Immunol 2005; 66: 938.
99. Popescu I, Macedo C, Abu-Elmagd K, et al. EBV-specific CD8+ T cell reactivation in transplant patients results in expansion of CD8 + type-1 regulatory T cells. Am J Transplant 2007; 7: 1215.
100. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T lymphocyte transfer. Blood 2007; 110: 2838.
101. Kleihauer A, Grigoleit U, Hebart H, et al. Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells. BrJHaematol 2001; 113:231.
102. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: A novel culture system free of live CMV virions. Blood 2001; 97: 994.
103. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375.
104. Lin CL, Lo WF, Lee TH, et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002; 62: 6952.
105. Fazle Akbar SM, FurukawaS,YoshidaO, etal. Induction ofanti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J Hepatol 2007; 47: 60.
106. Zabaleta A,LlopizD, ArribillagaL,etal. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. Mol Ther 2008; 16: 210.
107. Gruber A, Chalmers AS, Rasmussen RA, et al. Dendritic cell-based vaccine strategy against human immunodeficiency virus cladeC: Skewing the immune response toward a helper T cell type 2 profile. Viral Immunol 2007; 20: 160.
108. Comoli P, Basso S, Azzi A, et al. Dendritic cells pulsed with polyoma-virus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. J Am Soc Nephrol 2003; 14: 3197.
109. Bacci A, Montagnoli C, Perruccio K, et al. Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hema-topoietic transplantation. J Immunol 2002; 168: 2904.
110. Bozza S, Perruccio K, Montagnoli C, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003; 102: 3807.
111. Bauman SK, Nichols KL, Murphy JW. Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses. J Immunol 2000; 165: 158.